Debate Stirs Over Medicare Coverage For Proton Therapy In Prostate Cancer
This article was originally published in The Gray Sheet
Executive Summary
A private insurer is calling for CMS to issue a national non-coverage decision for proton therapy in treating prostate cancer, claiming Medicare payments will encourage rapid spread of the costly technology before there is enough clinical evidence to deem the treatment reasonable and necessary
You may also be interested in...
Reimbursement News In Brief
Vertebroplasty/Kyphoplasty tech assessment
Reimbursement News In Brief
Vertebroplasty/Kyphoplasty tech assessment
Evidence Lacking On Proton Therapy For Non-Small-Cell Lung Cancer – BCBS
Blue Cross Blue Shield’s Technology Evaluation Center found there is insufficient evidence that proton beam therapy improves health outcomes for patients with non-small-cell lung cancer.